ATE312621T1 - Pharmazeutische formulierungen von thyroidhormonen - Google Patents

Pharmazeutische formulierungen von thyroidhormonen

Info

Publication number
ATE312621T1
ATE312621T1 AT02014594T AT02014594T ATE312621T1 AT E312621 T1 ATE312621 T1 AT E312621T1 AT 02014594 T AT02014594 T AT 02014594T AT 02014594 T AT02014594 T AT 02014594T AT E312621 T1 ATE312621 T1 AT E312621T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulations
thyroid hormones
thyroid
hormones
framework
Prior art date
Application number
AT02014594T
Other languages
English (en)
Inventor
Alberto Garavani
Maurizio Marchiorri
Martino Alessandro Di
Echanagorria Angel Mateo
Original Assignee
Altergon Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11447983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE312621(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altergon Sa filed Critical Altergon Sa
Application granted granted Critical
Publication of ATE312621T1 publication Critical patent/ATE312621T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02014594T 2001-07-02 2002-07-02 Pharmazeutische formulierungen von thyroidhormonen ATE312621T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001401A ITMI20011401A1 (it) 2001-07-02 2001-07-02 Formulazioni farmaceutiche per ormoni tiroidei

Publications (1)

Publication Number Publication Date
ATE312621T1 true ATE312621T1 (de) 2005-12-15

Family

ID=11447983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02014594T ATE312621T1 (de) 2001-07-02 2002-07-02 Pharmazeutische formulierungen von thyroidhormonen

Country Status (9)

Country Link
US (1) US7723390B2 (de)
EP (1) EP1291021B1 (de)
JP (1) JP5105685B2 (de)
AT (1) ATE312621T1 (de)
CA (1) CA2392545C (de)
DE (1) DE60207951T2 (de)
DK (1) DK1291021T3 (de)
ES (1) ES2254559T3 (de)
IT (1) ITMI20011401A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022777A1 (it) 2002-12-27 2004-06-28 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
EP1762232A1 (de) * 2005-09-09 2007-03-14 Warner-Lambert Company LLC Flüssigkeit gefüllte Zufuhrsystem, vorzugweise ein HPMC Kapsel gefüllt mit Glycerol
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
JP2010503689A (ja) * 2006-09-19 2010-02-04 ジェンザイム コーポレーション 甲状腺刺激ホルモン（ｔｓｈ）の治療的投与のための配合物
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
IT1393524B1 (it) * 2009-01-30 2012-04-27 Altergon Sa Contenitore per uso farmaceutico atto al rilascio quantitativo di una monodose per somministrazione orale di ormoni tiroidei t3 e t4 in soluzione
IT1395454B1 (it) * 2009-03-24 2012-09-21 Altergon Sa Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
EP2461804A4 (de) * 2009-08-04 2013-10-02 Haren Treasurer Grösserer nutzen von schilddrüsenhormonen
DK2694471T3 (da) * 2011-04-08 2017-11-13 Bracco Imaging Spa Fremgangsmåde til fremstilling af et sulfateret derivat af 3,5-diiod-o-[3-iodphenyl]-l-tyrosin
ITMI20112066A1 (it) * 2011-11-14 2013-05-15 Altergon Sa Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4
DE102013017917A1 (de) * 2013-10-26 2015-04-30 Michael Raschke L-Thyrogal
US9345772B1 (en) 2015-02-27 2016-05-24 Nilesh Parikh Liquid levothyroxine formulations
EP3273948B1 (de) 2015-03-26 2020-02-12 Patheon Softgels Inc. Liquisoft-kapseln
US20170105955A1 (en) * 2015-05-19 2017-04-20 Altergon S.A. Liquid pharmaceutical formulations of tetraiodothyronine
ITUB20156821A1 (it) * 2015-12-09 2017-06-09 Altergon Sa CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
EP3311844A1 (de) 2016-10-18 2018-04-25 Altergon S.A. Hochstabile verpackte lösungen von t4-schilddrüsenhormon
JP6942342B2 (ja) * 2016-11-02 2021-09-29 富士カプセル株式会社 ソフトカプセル皮膜
US9782376B1 (en) 2016-12-01 2017-10-10 Fresenius Kabi Usa Llc Levothyroxine liquid formulations
IT201800003615A1 (it) 2018-03-15 2019-09-15 Altergon Sa Formulazioni altamente stabili di ormone tiroideo in capsule molli
US11241382B2 (en) 2019-03-01 2022-02-08 Altergon Sa Administration regimen of compositions of T4 thyroid hormone with high oral absorption
US20230338320A1 (en) 2019-11-22 2023-10-26 Wockhardt Limited Oral film composition comprising levothyroxine
US12451021B2 (en) 2022-08-04 2025-10-21 The Mitre Corporation Microscale weather hazard products for urban aviation transportation
IT202300020130A1 (it) 2023-09-29 2025-03-29 Ibsa Inst Biochimique Sa Formulazioni farmaceutiche stabili di amminoacidi, peptidi o proteine
WO2025253253A1 (en) 2024-06-04 2025-12-11 Ibsa Institut Biochimique Sa Orodispersible solid composition in the form of film for oral administration of thyroid hormones

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB876320A (en) 1956-11-08 1961-08-30 Glaxo Lab Ltd Pharmaceutical compositions containing d-3:5-diiodothyronine
US3157574A (en) * 1959-05-01 1964-11-17 Smith Kline French Lab Method of reducing cholesterol levels
US3855406A (en) * 1966-09-02 1974-12-17 Boots Co Ltd Thiaxanthene derivatives useful for treating peptic ulcers
US3808332A (en) * 1969-01-27 1974-04-30 Armour Pharma Pharmaceutical compositions containing the reaction product of a tertiary phosphine with thyroxine
US3851051A (en) * 1970-07-17 1974-11-26 Scherer R Corp Soft gelatin capsule containing high water content fill
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
DE4026600A1 (de) * 1990-08-23 1992-02-27 Henning Berlin Gmbh Mittel zur tsh-suppression und behandlung von struma
US5225204A (en) * 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
MX9703773A (es) * 1994-12-16 1997-08-30 Warner Lambert Co Proceso para la encapsulacion de capletas en una capsula y formas de dosis solidas que se puden conseguir mediante dicho proceso.
DE19541128C2 (de) * 1995-10-27 1997-11-27 Henning Berlin Gmbh & Co Stabilisierte schilddrüsenhormonhaltige Arzneimittel
US5635209A (en) * 1995-10-31 1997-06-03 Vintage Pharmaceuticals, Inc. Stabilized composition of levothyroxine sodium medication and method for its production
ATE271863T1 (de) * 1995-11-14 2004-08-15 Abbott Gmbh & Co Kg Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
US6197787B1 (en) * 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Also Published As

Publication number Publication date
ITMI20011401A0 (it) 2001-07-02
CA2392545C (en) 2012-12-18
EP1291021A2 (de) 2003-03-12
DE60207951D1 (de) 2006-01-19
DE60207951T2 (de) 2006-08-03
JP2003081870A (ja) 2003-03-19
JP5105685B2 (ja) 2012-12-26
DK1291021T3 (da) 2006-04-10
ES2254559T3 (es) 2006-06-16
US20030050344A1 (en) 2003-03-13
CA2392545A1 (en) 2003-01-02
EP1291021A3 (de) 2003-04-16
ITMI20011401A1 (it) 2003-01-02
EP1291021B1 (de) 2005-12-14
US7723390B2 (en) 2010-05-25

Similar Documents

Publication Publication Date Title
DE60207951D1 (de) Pharmazeutische Formulierungen von Thyroidhormonen
DK1083879T3 (da) Indretninger til at tilvejebringe forlænget medikamentterapi
EP1315533A4 (de) Programmierbare mehrdosenvorrichtung für intranasale medikamentenverabreichung
DK0494972T3 (da) Brusedosisform samt fremgangsmåde til administration heraf
DE60044041D1 (de) Exendine zur Glucagon Suppression
UY27186A1 (es) Formulación farmacéutica
NO20031018D0 (no) Oksymorfonpreparater med kontrollert frigivelse
DE60224284D1 (de) Stabile formulierung von modifiziertem glp-1
UY27789A1 (es) Metodos y modalidades de dosificación para la liberación controlada de oxicodona.
ATE317260T1 (de) Pharmazeutische formulierungen mit platinderivaten
CY1105170T1 (el) Συνταγοποιηση απο του στοματος δοσολογιας αστραπιαιας - τηξης
DK1389137T3 (da) Sammensætninger til lungelægemiddellevering af protein
DE60115418D1 (de) Mikroinfusionsvorrichtung zur verabreichung von medikamenten
DE60238131D1 (de) Pharmazeutische zubereitungen enthaltend kolloidales siliciumdioxid
IS7065A (is) Áætlun um lyfjaskammta við meðferð og lyfjasamsetningar til getnaðarvarna í neyð
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DK1112060T3 (da) Doseringsform anvendende flydende formulering
DK1433478T3 (da) Farmaceutiske formler til thyroidhormoner og fremgangsmåder til opnåelse af disse
HN2003000115A (es) Formulacion farmaceutica que comprende melatonina
NO20026055L (no) Farmasöytiske komponenter innbefattende humant paratyreoideahormon og farmasöytiske sammenstninger for nasal administrering inneholdendekomponentene
SE0200657D0 (sv) Novel Formulation
DE3869088D1 (de) Pharmazeutische zusammensetzungen.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1291021

Country of ref document: EP